Sage Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results
Top-line Results of Phase 3 STATUS Trial for SAGE-547 in SRSE Expected in 2H 2016
Robust, Wholly-Owned Pipeline Includes 6 Novel Compounds in Evaluation across Multiple CNS Indications
3 Clinical Data Readouts and Multiple Trial Initiations Anticipated Across Pipeline in 2016
Conference Call Today at
"2015 was a year of significant achievement for Sage and this success serves as the foundation for a potentially transformative year ahead. We are now poised to execute across a broad
pipeline of innovative CNS therapies as we evolve into a fully-integrated biopharmaceutical company," said
2015 Key Achievements and Recent Corporate Highlights
- Reported positive results from Phase 1/2 clinical trial of SAGE-547 in super-refractory status
epilepticus (SRSE), initiated Phase 3 STATUS Trial in SRSE and secured Special Protocol Assessment (SPA) with the
U.S. Food and Drug Administration(FDA)
- Reported promising early clinical proof-of-concept results of SAGE-547 in severe postpartum depression (PPD) and essential tremor, and initiated Phase 2 placebo-controlled clinical trial of SAGE-547 in severe PPD
- Initiated Phase 1 development program evaluating SAGE-217 in healthy volunteers
- Selected three next generation development candidates, including NMDA modulator SAGE-718 and GABA modulators SAGE-105 and SAGE-324
- Continue to strengthen organizational infrastructure and expanded leadership team with key development, research, technical operations and medical affairs appointments
- Ended 2015 with a strong balance sheet including cash and
cash equivalents as of
December 31, 2015of $186.8 million. In January 2016, Sage completed an underwritten public offering resulting in net proceeds of approximately $140.4 million.
Upcoming 2016 Pipeline Milestones
- Top-line data for Phase 3 STATUS Trial of SAGE-547 in SRSE expected in second half of 2016: The STATUS Trial is a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating SAGE-547 as a treatment for patients with SRSE, and is expected to enroll approximately 140 patients to achieve 126 evaluable patients with SRSE, ages two years or older.
- Top-line data for SAGE-547 in severe PPD expected during first half of 2016: Sage is conducting a Phase 2 placebo-controlled
clinical trial of SAGE-547 in patients with severe PPD. The multi-center study is planned to enroll up to 32 patients diagnosed with severe PPD and is intended to validate the activity signal observed in an initial open-label clinical trial.
- Top-line data for Phase 1 clinical program of SAGE-217 expected during first half of 2016: Sage is currently dosing subjects in the Phase 1 clinical development program evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effects of SAGE-217 in healthy adult volunteers. SAGE-217 is a next generation positive allosteric modulator that has been optimized for selectivity of synaptic and extrasynaptic GABAA receptors and for a pharmacokinetic profile allowing once-daily oral dosing.
- Potential Phase 2 clinical trial initiations for SAGE-217 in
multiple indications during the second half of 2016: If data from the ongoing Phase 1 clinical development program of SAGE-217 support further development, Sage plans to initiate up to three separate Phase 2 clinical trials with SAGE-217 in essential tremor, orphan epilepsies and potentially severe PPD, subject to positive results from the placebo-controlled clinical trial of SAGE-547 in severe PPD.
- Initiation of Phase 1 clinical development program for SAGE-689 during the second half of 2016: Sage anticipates beginning Phase 1 clinical development for SAGE-689, a next generation positive allosteric modulator of GABAA receptors that is being developed as an acute parenteral therapy for the treatment of indications where a high degree of anti-seizure activity and sedation are desirable prior to the introduction of general
anesthesia, such as status epilepticus. Planned commencement of the trial is tied to satisfaction of a request from the
U.S. Food and Drug Administration(FDA) for additional non-clinical study data.
- NMDA Program: In
November 2015, Sage announced the selection of SAGE-718 as its first NMDA development candidate. SAGE-718 is currently in IND-enabling studies and is being developed as a first-in-class, oxysterol-based positive allosteric modulator of NMDA receptors, a critical excitatory receptor system implicated in a broad range of CNS disorders. The initial indications selected by Sage for development are two NMDA-related orphan disorders - Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor Encephalitis, for which there are currently no approved treatments. Sage expects that SAGE-718 will begin clinical development in 2017.
Upcoming Events and Presentations
Epilepsy Foundation Pipeline Conference, San Francisco, February 26th Cowen and Company36th Annual Health Care Conference, Boston, March 7th American Chemical Society National Meeting & Exposition, San Diego, March 13th-17th American Academy of Neurology68th Annual Meeting , Vancouver, April 15th-21st
Fourth Quarter and Full Year 2015 Financial Results
- Cash Position: Cash and cash equivalents as of
December 31, 2015were $186.8 million, compared with $127.8 millionat December 31, 2014. In January 2016, Sage completed an underwritten public offering resulting in net proceeds of approximately $140.4 million.
- R&D Expenses: Research and development expenses were
$20.4 millionin the fourth quarter of 2015 and $69.4 millionfor the year ended December 31, 2015, compared to $8.9 millionand $24.1 millionin the comparable periods in 2014. The increase in R&D expense was primarily due to increased spending on clinical activities and the advancement of SAGE-547 into Phase 3 development and SAGE-217 into Phase 1 development, increased personnel-related R&D expenses supporting the advancement of SAGE's pipeline of programs, and increased non-cash stock-based compensation expense.
- G&A Expenses: General and administrative expenses were
$8.2 millionin the fourth quarter of 2015 and $25.3 millionin the year ended December 31, 2015, compared to $3.4 millionand $9.7 millionin the comparable periods in 2014. The increase in G&A expenses was primarily due to personnel-related costs, and professional fees associated with operating as a public company and costs related to general operations.
- Net Loss: Net loss was
$28.6 millionfor the fourth quarter and $94.5 millionfor the year ended December 31, 2015, compared to net loss of $12.4 millionand $36.1 millionfor the comparable periods of 2014.
- Financial Guidance: Based on its current operating plan, Sage expects that its existing cash and cash equivalents will be sufficient to fund its current operations into the beginning of 2018.
Conference Call Information
SAGE will host a conference call and webcast today at 8:30 AM ET to report its fourth quarter and full year 2015 financial results and discuss recent business updates. The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 49865237. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.
Various statements in this release concerning Sage's
future expectations, plans and prospects, including without limitation, our expectations regarding development of our product candidates and their potential in the treatment of various CNS disorders; the expected timing of clinical activities; the anticipated availability and announcement of data and results from clinical trials of our product candidates; the expected drivers and evolution of our business; and our expectations regarding the sufficiency of its cash position to fund operations. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may experience slower than expected clinical site
initiation, slower than expected identification and enrollment of evaluable patients, or potential need for additional analysis or data or the need to enroll additional patients, leading to possible delays in completion of trials or in the availability of data; we may not be able to generate supportive non-clinical data or to successfully demonstrate the efficacy and safety of our product candidates at each stage of development; success in our non-clinical studies or in early stage clinical trials may not be repeated or observed in ongoing or future studies involving the same compound or other product candidates, and future pre-clinical and clinical results may not support further development of product candidates or be sufficient to gain regulatory approval to market any product; decisions or actions of regulatory agencies may affect the initiation, timing, progress and cost of clinical
trials, and our ability to proceed with further clinical studies of a product candidate or to obtain marketing approval; the internal and external costs required for our activities, and to build the organization in connection with such activities, may be higher than expected; and we may encounter technical and other unexpected hurdles in the development and manufacture of our products, as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the
|Consolidated Balance Sheets|
|(in thousands, except share and per share data)|
|Cash and cash equivalents||$||186,753||$||127,766|
|Prepaid expenses and other current assets||1,738||1,056|
|Total current assets||188,491||128,822|
|Property and equipment, net||286||163|
|Deferred offering costs||200||-|
|Deferred tax assets||-||641|
|Liabilities and Stockholders' Equity|
|Deferred tax liabilities||-||641|
|Total current liabilities||15,307||7,757|
|Commitments and contingencies|
|Preferred stock, ||-||-|
|Common stock, ||3||3|
|Additional paid-in capital||335,032||188,727|
|Total stockholders' equity||173,695||121,885|
|Total liabilities and stockholders' equity||$||189,016||$||129,665|
|Consolidated Statements of Operations and Comprehensive Loss|
|(in thousands, except share and per share data)|
|Three Months Ended ||Twelve Months Ended |
|Research and development||20,376||8,945||69,357||24,100|
|General and administrative||8,236||3,416||25,293||9,710|
|Total operating expenses||28,612||12,361||94,650||33,810|
|Loss from operations||(28,612||)||(12,361||)||(94,650||)||(33,810||)|
|Interest income, net||63||4||178||8|
|Other expense, net||(13||)||(4||)||(23||)||(9||)|
|Net loss and comprehensive loss||(28,562||)||(12,361||)||(94,495||)||(33,811||)|
|Accretion of redeemable convertible preferred stock to redemption value||-||-||-||(2,294||)|
|Net loss attributable to common stockholders||$||(28,562||)||$||(12,361||)||$||(94,495||)||$||(36,105||)|
|Net loss attributable to common stockholders per common share - basic and diluted||$||(0.99||)||$||(0.48||)||$||(3.40||)||$||(1.67||)|
|Weighted-average shares outstanding - basic and diluted||28,810,565||25,605,622||27,778,288||21,574,347|
Paul Cox, Sage Therapeuticspaul.firstname.lastname@example.org 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLCmaureen.email@example.com 585-387-9248
News Provided by Acquire Media